samedan logo
 
 
 
spacer
home > ebr > summer 2003 > england - europe's low risk biotech location
PUBLICATIONS
European Biopharmaceutical Review

England - Europe's Low Risk Biotech Location

Scientists worldwide are celebrating the 50th anniversary of the deciphering of the structure of DNA. But in Cambridge there is special cause for celebration, for Crick and Watson made this ground-breaking discovery at the Cavendish Laboratory in Cambridge. Moreover, Sir John Sulston, winner of last year's Nobel Prize, is also a Cambridge scientist.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Jeanette Walker, Business Development Director at ERBI

Jeanette Walker is a graduate in Law and French from the University of Kent. She subsequently gained a Diploma in European Export Marketing from the University of Louvain in Belgium. She has worked in a variety of international business development roles, most recently as Head of New Business for Invest East of England, the regional inward investment agency.

In her current role at ERBI Jeanette also runs a wide range of programmes and events aimed at supporting and growing the biotech cluster in the East of England.

spacer
Jeanette Walker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera wins Pharmapack Award in Connected Devices and Wearables category with its body injector platform Symbioze

Symbioze, the smart, high volume and sustainable on-body injector platform developed by Nemera, wins the ‘Connected Devices and Wearables’ Award at Pharmapack 2021 On October 12th, during the Pharmapack Awards Ceremony, a team of industry experts awarded Symbioze, Nemera’s large-volume on-body injector, with the Pharmapack Award in the “Connected Devices and Wearables” category.
More info >>

White Papers

Running Smarter Trials With Data-Driven Monitoring

PAREXEL

Clinical monitoring remains one of the most important and most costly activities in the clinical research paradigm.  Monitoring provides the operational transparency required by investigators, sponsors, and regulators to make informed decisions about site performance, patient safety, and overall study progress. Yet unlike many clinical trial activities, which have been steadily transformed by technology, the monitoring function itself has changed little.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement